THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 11th, 2022 • Ocean Biomedical, Inc. • Pharmaceutical preparations
This Third Amendment to Exclusive License Agreement (this “Amendment”) is entered into as of March 25, 2022 (the “Amendment Date”), by and between Elkurt, Inc., a Rhode Island corporation with an address at 297 President Ave, Providence RI 02906 (“Elkurt”) and Ocean Biomedical Inc., a Delaware corporation with an address at 19W060 Avenue LaTours, Oak Brook, IL 60523 (“Licensee”).
THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 11th, 2022 • Ocean Biomedical, Inc. • Pharmaceutical preparations
This Third Amendment to Exclusive License Agreement (this “Amendment”) is entered into as of March 25, 2022 (the “Amendment Date”), by and between Elkurt, Inc., a Rhode Island corporation with an address at 297 President Ave, Providence RI 02906 (“Elkurt”) and Ocean Biomedical Inc., a Delaware corporation with an address at 19W060 Avenue LaTours, Oak Brook, IL 60523 (“Licensee”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • April 11th, 2022 • Ocean Biomedical, Inc. • Pharmaceutical preparations • Delaware
This REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of __________ [•], 2022 (the “Effective Date”), is entered into by and among Ocean Biomedical, Inc., a Delaware corporation (including such Party’s successors by merger, acquisition, reorganization or otherwise, the “Company”), and Poseidon Bio, LLC, a Delaware limited liability company (“Poseidon”). Capitalized terms that are used and not otherwise defined in this Agreement have the meanings set forth in Section 1.
AMENDMENT NO. 7 TO THE COMMON STOCK PURCHASE AGREEMENTCommon Stock Purchase Agreement • April 11th, 2022 • Ocean Biomedical, Inc. • Pharmaceutical preparations • Delaware
This Amendment No. 7 (this “Amendment”) to that certain Common Stock Purchase Agreement, dated as of June 23, 2021 (as amended and as may be amended, restated, supplemented or otherwise modified from time to time, the “Purchase Agreement”), by and among Ocean Biomedical, Inc., a Delaware corporation (the “Company”) and The Regents of the University of California, as Trustee of the University of California Retirement Plan (the “Purchaser”), is effective as of February 14, 2022, by and among the Company and the Purchaser. Terms used herein but not otherwise defined shall have the meanings as set forth in the Purchase Agreement.
LOAN AGREEMENTLoan Agreement • April 11th, 2022 • Ocean Biomedical, Inc. • Pharmaceutical preparations
This LOAN AGREEMENT dated as of February 22, 2022 (this “Agreement”), is entered by and between Ocean Biomedical, Inc., a Delaware corporation (“Borrower” or “Company”) and Second Street Capital, LLC, a California limited liability company (“Lender”). All capitalized terms used herein and not otherwise defined shall have the meanings provided hereof.
THIRD AMENDMENT TO EXCLUSIVE LICENSE AGREEMENTExclusive License Agreement • April 11th, 2022 • Ocean Biomedical, Inc. • Pharmaceutical preparations
This Third Amendment to Exclusive License Agreement (this “Amendment”) is entered into as of March 25, 2022 (the “Amendment Date”), by and between Elkurt, Inc., a Rhode Island corporation with an address at 297 President Ave, Providence RI 02906 (“Elkurt”) and Ocean Biomedical Inc., a Delaware corporation with an address at 19W060 Avenue LaTours, Oak Brook, IL 60523 (“Licensee”).
